Bundesamt für Verbraucherschutz und Lebensmittelsicherheit

Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL)
Federal Office of Consumer Protection and Food Safety
Gerichtstraße 49
13347 Berlin
(Germany)

DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Danilon equidos NF

Date: 08 May 2024

MODULE 1

PRODUCT SUMMARY

EU Procedure number	DE/V/0326/001/DC
Name, strength and pharmaceutical form	Danilon equidos NF 1.5g/sachet, granules
Applicant	Ecuphar NV Legeweg 157i B-8020 Oostkamp Belgium
Active substance(s)	Suxibuzone
ATC Vetcode	QM01AA90
Target species	Non food-producing horses and ponies
Indication for use	Supportive treatment of pain and inflammation of mild intensity associated with musculo-skeletal conditions in the horse e.g. osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation

MODULE 2

The Summary of Product Characteristics (SPC), the labelling and package leaflet for this veterinary medicinal product (VMP) is available in the Union Product Database (UPD).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Application in accordance with Article 13(3) of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	23 September 2020
Date product first authorised in the Reference Member State (MRP only)	n.a.
Concerned Member States for original procedure	AT, BE, CZ, DK, EE, HU, LV, LT, NO, PL, RO, SI, SK
Concerned Member States for subsequent recognition procedure	FR, IE, NL

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.
It has been shown that the product can be safely used in the target species; the reactions observed are indicated in the SPC[1].
The product is safe for the user, and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.
The product is a generic to the Spanish reference product 'Danilon équidos 150 mg/g granulado' of Ecuphar Veterinaria S.L.U. (459 ESP), which has been authorised in Spain on 15 July 1992 on the basis of a complete dossier. Bioequivalence of the product with the reference product was demonstrated. Therefore, the safety and efficacy of the product is identical to the reference product.
The overall risk/benefit analysis is in favour of granting a marketing authorisation.

[1] Summary of Product Characteristics

II. QUALITY ASPECTS

A. Qualitative and quantitative particulars

The product contains 1.5 g of the active substance suxibuzone (corresponds to 1.59 g of suxibuzone microencapsulated) and excipients tartrazine (E-102), mannitol, sucrose, povidone K-30, sodium saccharin and ethyl cellulose 20.

The product is presented in laminated opaline/aluminium polyethylene sachets with 3 g of granules per sachet as immediate packaging. Cartons with 18 or 60 sachets are marketed. As a measuring device a spoon made of high density polyethylene with 1.25 ml capacity (equivalent to 0.75 g of product) is added.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substance is suxibuzone, an established substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

D. Control on intermediate products

The tests performed during production are described and the results of 3 consecutive runs, conforming to the specifications, are provided.

E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production sites have been provided demonstrating compliance with the specification.

F. Stability

Stability data on the active substances have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

The claim of a 7 days' stability after broaching is based on the demonstration of stability for a batch broached and stored 7 days at +25°C.

G. Other Information

Not applicable.

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of safety studies are not required.

The pharmacology and toxicology aspects of this product are identical to the reference product, with the exception of the substitution of an excipient with tatrazine (E-102). The pharmacology and toxicology aspects of tatrazine have been evaluated.

User Safety

The applicant has provided a user safety assessment in compliance with the relevant guideline which shows all potential routes of accidental administration and confirms that the product is not expected to pose a risk for users when used as recommended. Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Environmental Risk Assessment

A Phase I environmental risk assessment (ERA) was provided according to the CVMP/VICH guidelines.

Phase I:

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the veterinary medicinal product will only be used in non-food animals and will be used to treat only a small number of animals.

IV. CLINICAL ASSESSMENT (EFFICACY)

This is a generic application according to Article 13 (3) of Directive 2001/82/EC, as amended. Although test and reference product are identical in terms of qualitative composition, a change in strength of the test product is proposed. Since bioequivalence with a reference product has been demonstrated, reference to the safety and efficacy documentation of the reference product is justified (EMA/CVMP/016/00-Rev.3) and additional studies are not required. The proposed indication, target species, route of administration and the already approved dose rate for this product are equivalent to those of the reference product.

IV.A Pre-Clinical Studies

Pharmacology

The applicant provided a bioequivalence study that has been conducted with the test product 'Danilon Equidos NF 1.5 g/sachet granules in sachet for horses and ponies' and the reference medicinal product 'Danilon équidos 150 mg/g granulado' authorized in Spain. The active substance in both test and reference product is suxibuzone. Bioequivalence of the test product and the reference product was demonstrated on the basis of the plasma concentrations of the main active metabolite phenylbutazone, as the 90% confidence intervals of the ratios of Cmax[2] and AUC[3] were within the stipulated range of 0.8 – 1.25.

[2] Maximum plasma concentration
[3] Area under the curve

Tolerance in the Target Species of Animals

As this application has been submitted in accordance with Art. 13(3) of Directive 2001/82/EC, as amended, and bioequivalence with the reference product has been demonstrated, results of target animal safety studies are not required. Given that the generic product will be administered to the same target species using the same posology and route of administration already approved for the reference product, it is concluded that a difference in tolerance profile is not to be expected. In addition, the product was well tolerated in the *in vivo* bioequivalence study.

IV.B Clinical Studies

Since this application has been submitted in accordance with Art. 13 (3) of Directive 2001/82/EC, as amended, and bioequivalence with the reference product has been demonstrated, clinical efficacy studies are not required and have not been provided. The efficacy claims for this product are equivalent to those of the authorized reference product.

V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available in the Union Product Database (UPD).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

Sequence of significant variations

Changes to Part 2 of the dossier (quality)

Summary of change (Application number)	Approval date
Introduction of a manufacturer of the active substance supported by an ASMF (DE/V/0326/001/A/001)	23/12/2022
One-off alignment of the product information with version 9.0 of the QRD template (DE/V/0326/001/A/002)	18/08/2023